Ameriprise’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Ameriprise’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,722,304	Closed	-$23.2M	–	3967
2024 Q1	$23.2M	Sell	4,722,304 -221,508	-4%	-$1.05M	0.01%	1218
2023 Q4	$18M	Buy	4,943,812 +500,483	+11%	+$1.37M	0.01%	1339
2023 Q3	$9.86M	Buy	4,443,329 +379,560	+9%	+$1.06M	﹤0.01%	1714
2023 Q2	$13.8M	Buy	4,063,769 +134,721	+3%	+$486K	﹤0.01%	1517
2023 Q1	$15.7M	Buy	3,929,048 +123,500	+3%	+$544K	0.01%	1437
2022 Q4	$20.7M	Sell	3,805,548 -47	-0%	-$277	0.01%	1209
2022 Q3	$19.1M	Buy	3,805,595 +34,328	+0.9%	+$169K	0.01%	1206
2022 Q2	$14.4M	Buy	3,771,267 +168,786	+5%	+$1.08M	0.01%	1454
2022 Q1	$25.5M	Buy	+3,602,481	New	+$25.3M	0.01%	1173

Ameriprise's TGAN Position: Q2 2024 in Review

Ameriprise sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 4,722,304 shares — an estimated $23.2M sold.

Ameriprise first reported a position in TGAN in Q1 2022 and held it in 9 quarters. The position peaked at $25.5M in Q1 2022. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Ameriprise reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Ameriprise sold 4,722,304 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $23.2M.
Ameriprise first reported a position in Transphorm, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
Ameriprise's Transphorm, Inc. Common Stock position peaked at $25.5M in Q1 2022.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Ameriprise's 13F filing for Q2 2024, filed 14 Aug 2024.